Effects of Sacubitril Valsartan Combined With Vericiguat on NT-proBNP and CK-MB Levels in Patients With Chronic Heart Failure.
Lijuan Jin, Tingting Yang
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial compared sacubitril/valsartan alone with sacubitril/valsartan plus vericiguat in 120 patients with chronic heart failure. After 6 months, the combination group showed greater improvement in NYHA functional class, echocardiographic measures, and 6-minute walk distance, alongside lower NT-proBNP and CK-MB levels. Endothelial function and inflammatory markers also improved more with combination treatment. Adverse reactions and cardiovascular events did not differ significantly between groups. The abstract reports no numerical effect estimates for these outcomes.
Key findings
- After 6 months, NYHA functional class improved more in the combination group than in the sacubitril/valsartan-only group.
- The combination group had lower NT-proBNP and CK-MB levels and more favorable ventricular dimensions and ejection fraction.
- Six-minute walk distance and endothelial function measures improved more with combination treatment; CRP and IL-6 were lower.
- Adverse reactions and cardiovascular events did not differ significantly between groups.
Why it matters
The findings suggest that adding vericiguat may provide broader functional, cardiac, and biomarker improvements in chronic heart failure than sacubitril/valsartan alone, without a detected increase in adverse events over the study period. The results are relevant to evaluating combination therapy, although the abstract provides no effect sizes to judge the magnitude of benefit.
What to keep in mind
The abstract gives no numerical effect estimates and reports outcomes only after a 6-month treatment period, limiting assessment of benefit magnitude and longer-term outcomes.